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OBJECTIVE—Evidence links the hypothalamic fatty acid syn-
thase (FAS) pathway to the regulation of food intake and body
weight. This includes pharmacological inhibitors that potently
reduce feeding and body weight. The mammalian target of
rapamycin (mTOR) is an intracellular fuel sensor whose activity
in the hypothalamus is also linked to the regulation of energy
balance. The purpose of these experiments was to determine
whether hypothalamic mTOR complex 1 (mTORC1) signaling is
involved in mediating the effects of FAS inhibitors.
RESEARCH DESIGN AND METHODS—We measured the
hypothalamic phosphorylation of two downstream targets of
mTORC1, S6 kinase 1 (S6K1) and S6 ribosomal protein (S6), after
administration of the FAS inhibitors C75 and cerulenin in rats.
We evaluated food intake in response to FAS inhibitors in rats
pretreated with the mTOR inhibitor rapamycin and in mice
lacking functional S6K1 (S6K1
/). Food intake and phosphor-
ylation of S6K1 and S6 were also determined after C75 injection
in rats maintained on a ketogenic diet.
RESULTS—C75 and cerulenin increased phosphorylation of
S6K1 and S6, and their anorexic action was reduced in rapamy-
cin-treated rats and in S6K1
/ mice. Consistent with our
previous ﬁndings, C75 was ineffective at reducing caloric intake
in ketotic rats. Under ketosis, C75 was also less efﬁcient at
stimulating mTORC1 signaling.
CONCLUSIONS—These ﬁndings collectively indicate an impor-
tant interaction between the FAS and mTORC1 pathways in the
central nervous system for regulating energy balance, possibly
via modulation of neuronal glucose utilization. Diabetes 57:
3231–3238, 2008
E
nergy balance is achieved when caloric intake is
matched to expenditure. A complex neuroendo-
crine system underlies this process and regu-
lates energy homeostasis in mammals. In
addition to sensing hormonal signals of stored fuels, such
as leptin (1), speciﬁc populations of neurons in the central
nervous system (CNS), and particularly within the hypo-
thalamus, have the ability to sense locally available nutri-
ents, including glucose (2), fatty acids (3), and amino acids
(4,5).
Recent evidence has highlighted the role of intracellular
fuel sensing in the regulation of energy balance (6). In
particular, the biochemical pathway underlying fatty acid
metabolism has been involved in the regulation of both
feeding and glucose homeostasis (6–10). Fatty acid syn-
thase (FAS) catalyzes the condensation of malonyl-CoA
and acetyl-CoA to generate long-chain fatty acids (LCFAs).
Acetyl-CoA carboxylase (ACC) and FAS are expressed in
the hypothalamus (7), where malonyl-CoA (11) and LCFA-
CoA levels (8) decrease during fasting and increase after
refeeding. Studies using FAS inhibitors and other pharma-
cological or genetic tools that modify the activity of
different enzymes regulating fatty acid metabolism sup-
port a role for this pathway in the regulation of feeding
(9,12–15).
Peripheral administration of the natural FAS inhibitor
cerulenin (2,3-epoxy-4-oxo-6-dodecadienoylamide) or the
synthetic inhibitor C75 (trans-4-carboxy-5-octyl-3-methyl-
enebutyrolactone) causes profound dose-dependent an-
orexia and weight loss in several rodent models
(12,13,15,16). Reduced food intake is also observed with
central administration of much lower doses of C75, sug-
gesting that the brain is the key site of action (12).
Increased hypothalamic malonyl-CoA is necessary for the
anorexic and weight-reducing effects of FAS inhibitors
(9,15,17). Interestingly, the ability of leptin to reduce food
intake depends on increased hypothalamic malonyl-CoA
(8) and possibly palmitoyl-CoA (18), which are achieved
through the concomitant inhibition of AMP-activated pro-
tein kinase (AMPK) and activation of ACC (18). Therefore,
the hypothalamic fatty acid synthesis pathway appears to
process different fuel signals and convert them into effer-
ent outputs that prevent further consumption of nutrients.
The mammalian target of rapamycin (mTOR) is a serine/
threonine kinase that controls critical aspects of cell
growth (19). mTOR is a component of at least two
multiprotein complexes: mTOR complex 1 (mTORC1),
which includes raptor, and mTOR complex 2 (mTORC2),
which includes rictor. Whereas mTORC2 regulates phos-
phorylation of Akt, mTORC1 modulates the activity of S6
kinase 1 (S6K1) and 4E binding protein 1 (20). Notably, the
phosphorylation of S6K1 at Thr 389 is one of the markers
commonly used to evaluate mTORC1 activity in vivo (21).
Insulin, IGF, amino acids, and glucose all activate intra-
cellular cascades that lead to activation of mTORC1 (22).
We reported that the anorexic action of central leptin and
leucine are both dependent on the activation of mTORC1
signaling in the hypothalamus (4). Given the ability of
mTORC1 to sense and integrate fuel signals, and the role it
plays in controlling food intake (4), we hypothesized that
mTORC1 signaling is involved in monitoring the biochem-
ical changes induced by the modulation of hypothalamic
fatty acid metabolism.
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Animals. Adult male Long-Evans rats, S6K1
/ mice, and their wild-type
littermates (23) were used. Mice were 8–11 weeks old in the cerulenin study
and 7 months old in the C75 study. All animals were housed individually and
maintained on a 12:12-h light-dark cycle, standard lab chow (Harlan-Teklad,
Indianapolis, IN), and water. All animal procedures were approved by the
institutional animal care and use committee of the University of Cincinnati.
Rats were implanted with intracerebroventricular (icv) cannulas as previously
described (24) and allowed to recover for a minimum of 7 days. Cannula
placement was conﬁrmed by consuming 5 ml water after 10 ng angiotensin
II icv.
Drugs. C75 (Calbiochem; EMD Bioscience, La Jolla, CA) was dissolved in
RPMI (Gibco, Carlsbad, CA). Cerulenin (Sigma-Aldrich, St. Louis, MO) was
ﬁrst dissolved in DMSO followed by RPMI, to a ﬁnal concentration of 25%
DMSO. Rapamycin (Calbiochem, EMD Bioscience) was dissolved in DMSO.
All vehicles served as controls.
Ketogenic diet. Rats were placed on a ketogenic diet (80.7% lipid, 14.3%
protein, and 5% carbohydrate calories; Dyet 100959; Dyets, Bethlehem, PA) for
4 weeks (13). Blood -hydroxybutyrate concentration was measured using the
KetoSite test (Stanbio Laboratory, Boerne, TX).
Leucine measurement. Plasma samples were deproteinized with sulfosali-
cylic acid and analyzed using an automated Hitachi L8800 Amino Acid
Analyzer.
Western blot. A wedge of mediobasal hypothalamus was dissected using as
landmarks the mammillary bodies caudally, the optic chiasm rostrally, the
optic tract laterally, and the apex of the third ventricle. Tissues were
homogenized in radioimmunoprecipitation assay buffer with addition of
phosphatase and protease inhibitors (Santa Cruz Biotechnology). Samples (70
g) were loaded on either a 9–13% (experiment 1) or a 10% (experiments 3
and 4) SDS-polyacrylamide gel (Bio-Rad). Proteins were separated by elec-
trophoresis and transferred to nitrocellulose membranes. Membranes were
processed as previously described (4) before overnight incubation at 4°C with
either phosphorylated S6K1 (pS6K1) at Thr 389 (1:500; Cell Signaling Tech-
nology, Beverly, MA) or phosphorylated S6 (pS6) at Ser 240/244 (1:500; Cell
Signaling Technology). After washing in Tris-buffered saline with Tween
(TBST), the membranes were incubated for1ha troom temperature with
secondary antibody conjugated with horseradish peroxidase (goat anti-rabbit;
1:2,000; Cell Signaling Technology). After washes in TBST, immunopositive
bands were visualized by chemiluminescence (Lumiglo reagent and peroxide
kit; Cell Signaling Technology) using exposure to radiographic ﬁlms (Denville
Scientiﬁc, South Plainﬁeld, NJ). After protein detection, membranes were
stripped for 15 min at 55°C with a solution containing 62.5 mmol/l Tris-HCl,
100 mmol/l 2-mercaptoethanol, and 2% SDS before 2-h blocking in TBST with
5% skim milk powder at room temperature and reblotted with either rabbit
anti–p70-S6K1 (Cell Signaling Technology, 1:250) or rabbit anti-S6 (1:500; Cell
Signaling Technology). Density was determined by National Institutes of
Health program Scion image.
Experimental design
Experiment 1: effect of C75 on hypothalamic mTORC1 signaling. One
hour before dark, rats were injected with C75 (30 gi n2l icv) or vehicle and
killed 30 min, 1 h, or 6 h later. Brains were removed, immediately frozen in
isopentane, and stored at 80°C until Western blot analysis.
Experiment 2: effect of rapamycin on C75-induced anorexia in rats.
Three hours before dark, rats were injected with either DMSO or rapamycin
(25 gi n1l icv) followed by RPMI or C75 (50 gi n3l icv) 2 h later. Food
was weighed at 1, 4, 8, and 24 h. Body weight was measured after 24 h. As
previously reported (18), we found that some CNS active compounds,
including leptin and C75, are less effective when animals are pretreated with
DMSO. In these conditions, the dose of C75 had to be raised to 50 g to reach
the same degree of anorexia as that observed with 30 g.
Experiment 3: anorexic actions of C75 and cerulenin in S6K1
/ mice.
One hour before dark, mice were injected intraperitoneally with C75 (20
mg/kg body wt), cerulenin (160 mg/kg body wt), or their respective vehicles;
and food was weighed at 1, 4, 10, and 24 h. Body weight was measured at 24 h.
The experiments used a within-subjects design with treatment order counter-
balanced and 1 week between each treatment.
Experiment 4: effect of cerulenin on hypothalamic mTORC1 signaling.
Rats were injected intracerebroventricularly with cerulenin (90 gi n2l) and
killed as in experiment 1.
Experiment 5: effect of the ketogenic diet on C75-induced anorexia.
Rats were divided into two groups (saccharin or sucrose). All rats had ad
libitum access to a ketogenic diet, water, and a sucrose or saccharin solution
(13). Four weeks later, rats were fasted for 24 h, and ketosis was conﬁrmed by
a signiﬁcant elevation of blood -hydroxybutyrate in rats that had access to
saccharin versus sucrose. Three days later, rats were fasted overnight and
given RPMI or C75 (30 gi n2l icv) 1 h before lights off. Food and bottles
of sucrose or saccharin were returned and weighed at 4 and 24 h.
Experiment 6: effect of the ketogenic diet on C75-induced changes in
pS6K1 and pS6. The protocol was the same as for experiment 5, except that
food, sucrose, and saccharin were not returned after the injection to avoid any
confounding effect of caloric intake. Rats were killed 1 h after receiving either
C75 or RPMI, and brains were collected for Western blot, as described above.
Statistical analyses. All values are expressed as means  SE. Data were
analyzed by two-way ANOVA for multiple group designs and one-way re-
peated measures ANOVA for within-subjects design, followed by Fisher’s least
signiﬁcant differences post hoc tests. Designs with only two groups were
assessed with unpaired t tests. Experiment-wise signiﬁcance was two-tailed
and set at P  0.05.
RESULTS
C75 increases hypothalamic mTORC1 signaling. C75
had no effect on the phosphorylation of either S6K1
(pS6K1/S6K1: RPMI, 100.00  8.36% vs. C75, 86.49 
11.68% of RPMI; P  0.365) or S6 (pS6/S6: RPMI, 100 
18.36% vs. C75, 105.59  14.45% of RPMI; P  0.816) 30 min
after injection. At 1 h, C75 increased the phosphorylation
of S6 (Fig. 1A and B), and at 6 h, this was accompanied by
a signiﬁcant elevation of pS6K (Fig. 1C and D).
mTORC1 signaling mediates the anorexic action of
C75. We have found that refeeding activates hypothalamic
mTORC1 signaling, whereas pharmacological inhibition of
CNS mTOR increases food intake in rats (4). Given that
C75 increased hypothalamic pS6K1 and pS6, we evaluated
whether C75-induced anorexia depends on activation of
the mTORC1 signaling by using the potent and selective
mTOR inhibitor rapamycin (25). There was a main effect of
the second drug treatment on food intake (F(1, 46)  29.03,
P  0.001). Within the 1st h after injection, C75 reduced
food intake (P  0.01), and this effect persisted for the
following 24 h (Fig. 2A and B). There was a main effect of
the ﬁrst drug treatment on food intake (F(1, 46)  5.53, P 
0.05). The dose of rapamycin used decreased feeding in
the 1st h (P  0.01; Fig. 2A), which was surprising given
that we had never observed an effect of this dose in any
prior studies (Appendix 1, which is available in an online
appendix at http://dx.doi.org/10.2337/db07-1690) (4).
Nonetheless, pretreatment with rapamycin blocked C75-
induced anorexia by4h( P  0.05; Fig. 2A), and the
inhibition persisted at 24 h (Fig. 2A and B). There was an
interaction between the ﬁrst and second drug treatments
on food intake at8h( F(1, 46)  4.16, P  0.05). There were
main effects of the ﬁrst (F(1, 46)  7.63, P  0.01) and
second drug treatments on body weight (F(1, 46)  10.57,
P  0.01). Rapamycin prevented the weight loss effect of
C75 over 24 h (P  0.05; Fig. 2C). The interaction between
the two drug treatments approached signiﬁcance (F(1, 46) 
4.03, P  0.05).
To assess the role of the mTORC1 pathway in mediating
the potent anorexic effects of FAS inhibitors, we used
S6K1
/ and their wild-type littermates. As previously
reported (26), S6K1
/ mice had lower body weights than
wild-type mice (wild type, 29.36  1.30 vs. S6K1
/,
25.60  0.78 g; P  0.05). However, their cumulative 24-h
food intake was similar to that of controls, whether
expressed as total intake (Fig. 2E) or intake per kilogram
body weight (wild type/RPMI, 139.68  26.99 vs. S6K1
/
/RPMI, 156.38  15.52 g/kg body wt; P  0.603). There
was a main effect of drug on feeding (F(1, 10)  30.07, P 
0.001). C75 signiﬁcantly decreased food intake in both
genotypes in the 1st h (P  0.01; Fig. 2D). The suppression
lasted at least 24 h in wild-type mice (P  0.01; Fig. 2D and
E). However, the response of S6K1
/ mice was signiﬁ-
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main effect of genotype (F(1, 10)  5.69, P  0.05). There
was a signiﬁcant interaction between drug and genotype
between 10 and 24 h (F(1, 10)  7.06, P  0.05), even when
expressed as grams per kilogram body weight (interval
10–24 h: wild type/C75, 8.95  5.72 vs. S6K1
//C75,
29.34  6.21 g/kg body weight; P  0.05). We also found a
main effect of drug on weight loss (F(1, 10)  49.28, P 
0.001), and there was a trend for C75 to be less potent in
S6K1
/ (P  0.077; Fig. 2F). Thus, the pharmacological
and genetic data imply that intact mTORC1 signaling is
necessary for the full anorexic effect of C75 in rats and
mice at time points beyond 4 h.
Cerulenin activates hypothalamic mTORC1 signaling,
and this effect is required for its anorexic action.
Because no pharmacological agent is speciﬁc to a single
pathway, we further tested our hypothesis by using a
second FAS inhibitor. Cerulenin activated mTORC1 signal-
ing in a pattern similar to that of C75 by phosphorylating
both S6K1 and S6 (Fig. 3A and B). Moreover, cerulenin
also required intact mTORC1 signaling to cause anorexia.
Consistent with previous reports (15,16), cerulenin de-
creased food consumption, as revealed by a main effect of
drug that started 1 h after injection in both genotypes
(F(1, 13)  33.61, P  0.001). This effect persisted in the
following 4- to 24-h period in wild type (P  0.001), but not
in S6K1
/, whose food consumption was similar to that
of VEH-injected S6K1
/ after 4 h (Fig. 3C). There was
also a main effect of drug on 24-h weight loss (F(1, 13) 
22.00, P  0.001), but only in wild type (Fig. 3E). There
was a trend for an interaction between genotype and drug
on feeding at 4 h, which reached signiﬁcance at 24 h
(F(1, 13)  15.84, P  0.01; Fig. 3D) and was also found for
weight loss (F(1, 13)  10.61, P  0.01; Fig. 3E). The
observation that two different FAS inhibitors modulate
hypothalamic mTORC1 and require mTORC1 signaling for
their anorexic action makes a strong case for a link
between mTORC1 and FAS in the regulation of feeding.
The actions of C75 on hypothalamic mTORC1 signal-
ing are blunted in ketotic rats. We had previously
hypothesized that a key signal leading to C75-induced
anorexia is derived, at least in part, from its ability to
increase CNS glucose utilization, and we demonstrated
that C75 does not reduce food intake under ketosis (13).
Here, we explored the possibility that this is due to
inability to modulate CNS mTORC1 signaling. Blood -hy-
droxybutyrate was signiﬁcantly elevated in rats given
access to saccharin versus sucrose (P  0.001; Fig. 4A).
There was a main effect of drug on food intake at 4 h
(F(1,28)  12.74, P  0.01) and at 24 h (F(1,28)  9.33, P 
0.01). Consistent with its effect on chow, C75 reduced
caloric intake in rats whose ketosis was prevented by
access to sucrose (P  0.01), and this effect lasted for 24 h.
However, the caloric-reducing effect of C75 was blunted in
ketotic rats receiving saccharin at 4 (data not shown) and
24 h (Fig. 4B) and was nearly statistically different from
that of rats in the sucrose group (P  0.059; Fig. 4B). These
effects were accompanied by reduced hypothalamic
mTORC1 signaling in ketotic rats compared with sucrose
rats. There was a main effect of drug on pS6K1 (F(1,27) 
5.56, P  0.05) and pS6 (F(1,26)  27.19; P  0.001). The
effect of diet (F(1,26)  3.89, P  0.059) and the interaction
between drug and diet (F(1,26)  3.92, P  0.058) nearly
reached statistical signiﬁcance for pS6. C75 was less
efﬁcient at increasing pS6 in ketotic rats versus sucrose
rats (P  0.05; Fig. 4D), and it increased pS6K1 only in
sucrose rats (P  0.01) (sucrose-C75 vs. saccharin-C75,
P  0.05; Fig. 4C). Thus, the anorexic action of C75
appears to depend on the rate of neuronal glucose uptake
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ability of C75 to modulate mTORC1 signaling.
Ketosis is known to induce profound metabolic changes
(27), so we compared sucrose- versus saccharin-treated
rats on the same gel. Ketosis had no signiﬁcant effect on
the basal phosphorylation of S6K1 but caused a nonsignif-
icant increase in S6 phosphorylation (Appendix 2, which is
available in the online appendix). Rats fed a ketogenic diet
have increased leucine levels in the cerebral cortex (28).
Given the important role of leucine in regulating mTOR
(29,30), we determined whether the ketogenic diet
changes plasma leucine levels. However, we did not ﬁnd
any difference in circulating leucine between the two
groups (Fig. 4E).
DISCUSSION
Modulation of the FAS pathway represents a therapeutic
strategy to produce weight loss and points to the impor-
tant role of CNS metabolic pathways in regulating energy
balance (6,31). Our previous work has demonstrated that
activation of mTORC1 signaling in the hypothalamus re-
duces food intake (4). This led us to hypothesize that the
ability of FAS inhibitors to modulate hypothalamic
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FAS INHIBITORS REGULATE CNS mTORC1
3234 DIABETES, VOL. 57, DECEMBER 2008mTORC1 signaling is an important mechanism by which
they cause anorexia.
Here, we report that central administration of C75 or
cerulenin increases phosphorylation of hypothalamic
S6K1 and S6. Furthermore, the ability of these compounds
to modulate feeding depended on the activation of CNS
mTORC1 signaling. In fact, intracerebroventricular rapa-
mycin dampened the ability of C75 to reduce both feeding
and body weight (4). We were surprised to observe an
effect of rapamycin to reduce feeding in the 1st h after
injection, given that we had not seen an effect of this dose
in several prior studies (Appendix 1) (4). Nonetheless, it is
important to point out that this effect on food intake is
short-lived, with no effect observed beyond 1 h. Impor-
tantly, rapamycin actually resulted in an increase in intake
in the presence of C75, which is incompatible with a major
effect of rapamycin to reduce food intake.
Although rapamycin is quite speciﬁc in its effect on
mTORC1 signaling (4), pharmacological inhibitors can
have drawbacks that limit the interpretation of experi-
mental results. Hence, we further tested our hypothesis
in mice lacking S6K1, a key component of the mTORC1
pathway. C75 or cerulenin reduced both food intake and
body weight in wild-type mice, as reported before
(17,32). However, this effect was signiﬁcantly reduced in
S6K1
/ mice. Interestingly, the data arising from both
the pharmacological and genetic studies indicate that
the activity of the mTORC1 pathway critically contrib-
utes to the anorexic effects of FAS inhibitors 4 h after
drug injection. The time course observed in S6K1
/
mice is a remarkable match for the observation made in
rats that activation of mTORC1 remains elevated 6 h
after either C75 or cerulenin. Such data underscore the
importance of the mTORC1 signaling as one component
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from VEH-treated or CERU-treated (90 gi n2l RPMI-DMSO icv) rats and
quantiﬁcation by image analysis of hypothalamic phosphorylation of S6K1
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/ mice. E: Body weight change over 24 h in mice injected
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K. PROULX AND ASSOCIATES
DIABETES, VOL. 57, DECEMBER 2008 3235of a cascade that is essential to the anorexic effects of
FAS inhibitors.
One proposed mechanism by which FAS inhibitors
suppress food ingestion is by increasing CNS glucose
utilization (13). Glucose metabolism is a biochemical
index of nutrient status that plays a key role in the control
of feeding. Quantitative and temporal changes in glucose
concentration are closely monitored and integrated by
speciﬁc subpopulations of “glucosensing” neurons in the
CNS that are crucial to the regulation of feeding (6). A key
ﬁnding to support the involvement of increased glucose
use in mediating the effect of FAS inhibition is that rats on
a very low carbohydrate diet, which forces them to
produce ketone bodies that neurons use in preference to
glucose (33), do not reduce their food intake in response
to C75 (13). In accordance with those previous results, we
observed that rats maintained on a ketogenic diet but
given sucrose to prevent ketosis responded to C75. In
contrast, rats maintained on the ketogenic diet but given
saccharin did not signiﬁcantly reduce their food intake
after C75. C75 increased S6 phosphorylation in rats on the
ketogenic diet supplemented with sucrose, but this effect
is blunted in those on the same diet supplemented with
saccharin. This effect is consistent with what has been
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increases the phosphorylation of S6K1 1 h after injection
under a ketogenic diet supplemented with sucrose,
whereas this phenomenon happens only at 6 h under a
chow diet. This is an issue that we tested several times
with multiple time points. In several studies, there was a
strong trend for increased pS6K1 at 1 h, but this effect was
not consistent across experiments, unlike the reliable
effect to increase pS6. There could be a number of
possibilities to explain why the time course of C75-
induced phosphorylation of S6K1 differs between the two
diets. The ketogenic diet induces a wide range of meta-
bolic effects in addition to reducing glucose availability
(27). These differences provide an important rationale for
why we used the ketogenic diet supplemented with su-
crose instead of a normal chow diet as the control for
experiment 4. Nonetheless, these ﬁndings not only point to
the permissive role played by neuronal glucose metabo-
lism in the FAS inhibitors-induced anorexia, but they also
highlight a mechanism through which the inhibition of
FAS leads to the modulation of the mTORC1 signaling.
Kim et al. (17) ascribed the anorexic action of C75 to its
ability to inhibit hypothalamic AMPK. Like mTOR, AMPK
is a fuel sensor that plays a critical role in integrating
signals of energy status in the hypothalamus and regulat-
ing food intake. However, in contrast to mTOR, hypotha-
lamic AMPK is activated during negative energy balance,
in which case it stimulates feeding (34). The relationship
between these two fuel sensors is rather complex and
appears to be bidirectional (35,36). Given the highly regu-
lated crosstalk between mTOR and AMPK, the current
experiments cannot rule out whether the effects of C75 on
the mTORC1 pathway are directly mediated or occur as a
result of inhibition of hypothalamic AMPK. Nonetheless,
the data of Kim et al. (17) suggest that AMPK activity is
involved primarily in the short-term actions of C75 be-
cause AMPK activators inhibit the effect of C75 speciﬁcally
during the 1st h after drug administration, whereas our
data suggest that mTORC1 signaling might be critical at
later time points.
In conclusion, we provide evidence that links the FAS
pathway to the mTORC1 signaling cascade in the CNS and,
although the current experimental design does not allow
us to conclude whether the ability of FAS inhibition to
reduce food intake is due exclusively to actions in the
hypothalamus, the literature would argue that it is the
case. Several studies have attributed the hypophagic ac-
tion of FAS inhibition to direct effects on hypothalamic
neurons (31,37–40), and this model has been further
supported in the recent study of Chakravarthy et al. (40).
This group demonstrated that genetic inactivation of FAS
in the hypothalamus and -cells results in anorexia en-
tirely due to inactivation of the enzyme in the hypothala-
mus. Moreover, nutritional regulation of mTORC1
signaling occurs speciﬁcally in the hypothalamus (4).
Taking into account that leptin also activates mTORC1 in
the hypothalamus (4) and reduces food intake through
actions on CNS fatty acid metabolism (18), this suggests
that mTORC1 is an important integrator of multiple signals
in the CNS. mTORC1 activity can be found in both
agouti-related protein– and proopiomelanocortin-produc-
ing neurons in the arcuate nucleus (4), and, thus, in-
creased mTORC1 activity in the CNS may contribute to the
similar effects of C75 and leptin on both food intake and
hypothalamic gene expression (15,17,41). The current data
connect two separate metabolic pathways that have been
independently implicated in the CNS regulation of energy
balance, thus providing new knowledge on the relation-
ship among key signaling pathways able to affect feeding
behavior. Identifying the speciﬁc metabolic signals that
are integrated by energy-sensing neurons is a crucial
scientiﬁc question that could give important insights into
potential etiologies and therapies for obesity and other
metabolic disorders.
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